RxDoctor Payments Data

Kc Bens, MD

Urology · Dallas, TXNPI 1568825735

Payments from drug & device makers

$7,447in general payments, 2019–2025

Across 213 payments — averaging $34.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Sumitomo Pharma America, Inc.$547
  • Procept Biorobotics Corporation$503
  • Boston Scientific$470
  • Johnson & Johnson$394
  • Coloplast$337
  • plus $3K from 37 others

What the payments were for

  • Travel & lodging$1,50820%
  • Food & beverage$5,65776%
  • Education$1352%
  • Gifts$1472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,447 in reported general payments places this provider in the 65th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$208,214
Medicare patients
199
Services billed
5,628

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide20$275,450
ErleadaApalutamide13$181,566
OrgovyxRelugolix65$168,849
GemtesaVibegron121$144,463
MyrbetriqMirabegron163$98,045
Estradiol285$17,525
Tamsulosin Hcl245$2,645
Ciprofloxacin Hcl168$1,217
Tadalafil14$1,051
Finasteride47$644
Metronidazole19$569
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip17$460
CefuroximeCefuroxime Axetil31$371
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim75$329
NitrofurantoinNitrofurantoin Macrocrystal17$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$323$373,495183 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$547$313,312186 claims
Johnson & JohnsonErleada$394$181,56613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 878 urology providers in Texas.

Other urology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →